Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny

benzinga.com/news/fda/25/06/46101643/did-the-fda-make-a-mistake-sareptas-elevidys-approval-under-scrutiny

The Food and Drug Administration (FDA) on Tuesday said it is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Sarepta Therapeutics, Inc.’s (NASDAQ:SRPT) Elevidys treatment and evaluating the need for further regulatory…

This story appeared on benzinga.com, 2025-06-25 18:06:40.
The Entire Business World on a Single Page. Free to Use →